Inhibition of the metabolism of brotizolam by erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in brotizolam metabolism

British Journal of Clinical Pharmacology

Volumn 60, Issue 2, 2005, Pages 172-175

  Tokairin, Takaki ^a   Fukasawa, Takashi ^a   Yasui Furukori, Norio ^b   Aoshima, Toshiaki ^a   Suzuki, Akihito ^a   Inoue, Yoshimasa ^c   Tateishi, Tomonori ^b   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Mitsubishi Pharma   (Japan)

Author keywords

Brotizolam; CYP3A4; Erythromycin; Metabolism

Indexed keywords

BROTIZOLAM; CYTOCHROME P450 3A4; ERYTHROMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AZEPINES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ERYTHROMYCIN; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PROTEIN SYNTHESIS INHIBITORS;

EID: 23044506564     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02380.x     Document Type: Article

References (14)

1. Langley MS, Clissold SP. Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 1988; 35: 104-22.
2. Wilkinson GR. Cytochrome P4503A (CYP3A9) metabolism: prediction of in vivo activity in humans. J Pharmacokin Biopharm 1996; 24: 475-90.
3. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996; 59: 514-9.
4. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 1996; 139: 269-73.
5. Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, Sugawara K. Effect of carbamazepine on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Neuropsychopharmacology 1998; 18: 364-9.
6. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305.
7. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998;64:278-85.
8. Araki K, Yasui-Furukori N, Fukasawa T, et al. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 2004; in press.
9. Senda C, Kishimoto W, Sakai K, Nagakura A, Igarashi T. Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica 1997; 27: 913-22.
10. Wechsler D. Wechsler Adult Intelligence Scale-Revised. Harcourt Brace Jovanovich, New York NY. 1996.
11. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973; 10: 431-6.
12. Hikida K, Inoue Y, Nouchi E, Ohkura Y. Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography. Jpn J Clin Chem 1990; 19: 354-9.
13. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16: 337-64.
14. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 1993; 24: 453-71.